Private equity firms such as Warburg Pincus and CVC Capital Partners have evinced interest in Orbicular Pharma as the specialty pharma firm explores a stake sale in a deal that will likely value the company up to $1.5 billion.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.